|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Amiloride#Contraindications]] |
| {{Amiloride}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Contraindications==
| |
| | |
| ===Hyperkalemia===
| |
| | |
| MIDAMOR should not be used in the presence of elevated serum potassium levels (greater than 5.5 mEq per liter).
| |
| | |
| Antikaliuretic Therapy or Potassium Supplementation
| |
| | |
| MIDAMOR should not be given to patients receiving other potassium-conserving agents, such as spironolactone or triamterene. Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with MIDAMOR except in severe and/or refractory cases of [[hypokalemia]]. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary.
| |
| | |
| ===Impaired Renal Function===
| |
| | |
| Anuria, acute or chronic [[renal insufficiency]], and evidence of diabetic nephropathy are contraindications to the use of MIDAMOR. Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or [[diabetes mellitus]] should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. Potassium retention associated with the use of an antikaliuretic agent is accentuated in the presence of renal impairment and may result in the rapid development of [[hyperkalemia]].
| |
| | |
| ===Hypersensitivity===
| |
| | |
| MIDAMOR is contraindicated in patients who are [[hypersensitive]] to this product.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MIDAMOR (AMILORIDE HYDROCHLORIDE) TABLET [PADDOCK LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4cde6e4-12cb-4e30-920f-5b94576b4863 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Sodium channel blockers}}
| |
| {{Diuretics}}
| |
| | |
| [[Category:Potassium-sparing diuretics]]
| |
| [[Category:Aminopyrazines]]
| |
| [[Category:Guanidines]]
| |
| [[Category:World Health Organization essential medicines]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |